The problem
Heart failure and vascular disease develop gradually, and standard care — medication, procedures, rehabilitation — is built to protect the capacity that remains.
Alongside that protection, regenerative protocols pursue a further goal: supporting repair in the working tissue itself.
Every protocol is designed according to each patient’s biology, medical history, and goals.
The approach
Every Neorgana protocol is customized and multifactorial — built around the patient’s unique case by a multidisciplinary team, with expert guidance at every step.
It begins with thorough assessment and functional review. Supportive therapies prepare the body and create the right environment; regenerative therapies are administered when the patient is ready; and integration care continues afterward — because regeneration is more than any single administration.
For cardiometabolic and vascular health, a plan may draw on cellular and signaling therapies from the Dezawa platform with metabolic and vascular support — combined according to the case.
Every protocol is designed according to each patient’s biology, medical history, and goals.
The cardiac human trial on the platform behind Neorgana’s cellular therapies. Published on PubMed.
02Human myocardial research on the platform. Published on PubMed.
03Peer-reviewed research on the Muse cell platform, with links to the original journals.
04The platform’s research library, maintained by MuseCell Innovations®, the global IP owner.
The science
Dezawa MuseCells® were discovered and developed by Dr. Mari Dezawa — Professor and Director of the Department of Stem Cell Biology and Histology at Tohoku University School of Medicine, and one of the most respected scientists in regenerative medicine. They reach Neorgana exclusively through MuseCell Innovations®, the global IP owner.
Browse the publicationsWe respect your privacy. Opening the language menu loads Google Translate, which sets its own cookies.
